Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

PURPOSE: Based on promising predinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2(mut) nonamplified metastatic breast cancer (MBC). Secondary endpoints i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ma, Cynthia X., Bose, Ron, Gao, Feng, Freedman, Rachel A., Telli, Melinda L., Kimmick, Gretchen, Winer, Eric, Naughton, Michael, Goetz, Matthew P., Russell, Christy, Tripathy, Debu, Cobleigh, Melody, Forero, Andres, Pluard, Timothy J., Anders, Carey, Niravath, Polly Ann, Thomas, Shana, Anderson, Jill, Bumb, Caroline, Banks, Kimberly C., Lanman, Richard B., Bryce, Richard, Lalani, Alshad S., Pfeifer, John, Hayes, Daniel F., Pegram, Mark, Blackwell, Kimberly, Bedard, Philippe L., Al-Kateb, Hussam, Ellis, Matthew J.C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6746403/
https://ncbi.nlm.nih.gov/pubmed/28679771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0900
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados